Amyotrophic Lateral Sclerosis (ALS)

Pioglitazone Benefits Mice But Not Man

The anti-diabetic drug pioglitazone did not improve survival time when tested as an add-on therapy to riluzole in a phase 2 clinical trial of people with amyotrophic lateral sclerosis (ALS).

The trial, which was conducted in Germany, was stopped early "for futility" when interim results showed no effects on survival. (A futility trial is one that is designed to stop at a designated point if it's clear that the drug is not having the intended effect.)

Patient Assistance Program Launched for Nuedexta

A new Patient Assistance Program can help people with a diagnosis of pseudobulbar affect (PBA) get a medication designed to treat the condition at low or no cost.

MDA Symposium Puts Glial Cells in the Spotlight

The contribution of nervous system support cells called glia to the degeneration of motor neurons in amyotrophic lateral sclerosis (ALS)was the topic of serious discussion among researchers at MDA's Neuron Symposium on May 22, 2012.

The meeting, held at MDA's national headquarters in Tucson, Ariz., brought together ALS researchers studying the toxic role played in that disease by glia, and scientists who specialize in these key support cells.

MDA Launches New Research Symposium Series

This month, MDA is launching a new U.S.-based symposium series to address important topics and ultimately to accelerate therapy development for neuromuscular diseases.

"MDA’s new symposium series is designed to address cutting-edge issues in neuromuscular disease research," said Sanjay Bidichandani, MDA's vice president of research. "Science is advancing at a rapid pace, and these small and focused meetings will allow us to be nimble in tackling multiple issues every year."

Neuralstem Seeks to Expand Stem Cell Trial

The biotherapeutics company Neuralstem is seeking to amend the design of its ongoing phase 1 stem cell trial in amyotrophic lateral sclerosis (ALS) to include evaluations of efficacy (how well the therapy works).

Although the phase 1 trial isn’t currently designed to evaluate efficacy, early results reported in March noted that one participant showed signs of clinical improvement.

ALS Research Briefs: News from 2012 AAN Conference

Among the reports given at the 2012 annual meeting of the American Academy of Neurology, being held April 21-28 in New Orleans, was information about research into amyotrophic lateral sclerosis (ALS).

Neuromuscular Disease Research Discussed at 2012 AAN Meeting

Top scientists and clinicians from around the world are discussing the latest research in neuroscience, and the care of individuals with nerve and muscle diseases, at the 2012 annual meeting of the American Academy of Neurology in New Orleans, April 21-28.

MDA 2012 Clinical Conference Report: ALS Best Practices

Several experts presented their views of best practices for care of people with ALS at MDA's 2012 Clinical Conference, held in Las Vegas March 4-7.

Best practices outlined in this article include:

MDA 2012 Conference Report: Best Practices

Several experts presented their views of "best practices" for care of people with neuromuscular disorders at MDA's 2012 Clinical Conference, held in Las Vegas March 4-7.

Many questions remain about optimal care in these disorders, but it's clear that attention to heart and respiratory function are of paramount importance.

This article looks at:

ALS Research Briefs: SOD1, Repeat Expansions

SOD1 causes toxicity in some familial and some sporadic ALS

In some people with bulbar-onset sporadic ALS, changes to the SOD1 protein cause the same toxicity as is generated by mutated SOD1 protein in the familial (inherited) form of the disease, a team of researchers has reported.

Pages